Six years ago, Daniel Mandell appeared on NPR to talk about an invention out of Jurassic Park. As Crichton and Goldblum fans recall, International Genetic Technologies, Inc.’s contingency plan to...
Read More
BOSTON, November 3, 2021 – GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of a Series A financing
GRO Biosciences Inc. wants to make a giant sector in the pharmaceutical industry even larger. The spinout from the lab of Harvard Medical School geneticist George Church aims to make protein drugs more versatile and effective